4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Eika S. Webb, Peng Liu, Renato Baleeiro, Nicholas R. Lemoine, Ming Yuan, Yaohe Wang. Immune checkpoint inhibitors in cancer therapy[J]. The Journal of Biomedical Research, 2018, 32(5): 317-326. DOI: 10.7555/JBR.31.20160168
Citation: Eika S. Webb, Peng Liu, Renato Baleeiro, Nicholas R. Lemoine, Ming Yuan, Yaohe Wang. Immune checkpoint inhibitors in cancer therapy[J]. The Journal of Biomedical Research, 2018, 32(5): 317-326. DOI: 10.7555/JBR.31.20160168

Immune checkpoint inhibitors in cancer therapy

Funds: 

This work was supported by The MRC DPFS grant (MR/M015696/1) and Ministry of Sciences and Technology of China (2013DFG32080).

More Information
  • Received Date: December 15, 2016
  • In recent years immune checkpoint inhibitors have garnered attention as being one of the most promising types of immunotherapy on the horizon. There has been particular focus on the immune checkpoint molecules, cytotoxic Tlymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) which have been shown to have potent immunomodulatory effects through their function as negative regulators of T cell activation. CTLA-4, through engagement with its ligands B7-1 (CD80) and B7-2 (CD86), plays a pivotal role in attenuating the activation of na?ve and memory T cells. In contrast, PD-1 is primarily involved in modulating T cell activity in peripheral tissues via its interaction with PD-L1 and PD-L2. The discovery of these negative regulators of the immune response was crucial in the development of checkpoint inhibitors. This shifted the focus from developing therapies that targeted activation of the host immune system against cancer to checkpoint inhibitors, which aimed to mediate tumor cell destruction through the removal of coinhibitory signals blocking anti tumor T cell responses.
  • Related Articles

    [1]Ya Xie, Zifeng Xu, Yumin Zhang, Yisheng Li, Pengyu Du, Chun Wang. First-episode psychiatric disorder risk from SARS-CoV-2 infection: A clinical analysis with Chinese psychiatric inpatients[J]. The Journal of Biomedical Research, 2025, 39(1): 50-60. DOI: 10.7555/JBR.38.20240005
    [2]Zheyue Wang, Qi Tang, Bende Liu, Wenqing Zhang, Yufeng Chen, Ningfei Ji, Yan Peng, Xiaohui Yang, Daixun Cui, Weiyu Kong, Xiaojun Tang, Tingting Yang, Mingshun Zhang, Xinxia Chang, Jin Zhu, Mao Huang, Zhenqing Feng. A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling[J]. The Journal of Biomedical Research, 2023, 37(3): 166-178. DOI: 10.7555/JBR.36.20220221
    [3]Jiao Chen, Can Zhao, Yingzi Huang, Hao Wang, Xiang Lu, Wei Zhao, Wei Gao. Malnutrition predicts poor outcomes in diabetic COVID-19 patients in Huangshi, Hubei[J]. The Journal of Biomedical Research, 2022, 36(1): 32-38. DOI: 10.7555/JBR.35.20210083
    [4]Liu Zhi, Wang Jianwei, Ge Yiyue, Xu Yuyu, Guo Mengchen, Mi Kai, Xu Rui, Pei Yang, Zhang Qiankun, Luan Xiaoting, Hu Zhibin, Chi Ying, Liu Xingyin. SARS-CoV-2 encoded microRNAs are involved in the process of virus infection and host immune response[J]. The Journal of Biomedical Research, 2021, 35(3): 216-227. DOI: 10.7555/JBR.35.20200154
    [5]Chen Wei, Hu Zhiliang, Yi Changhua, Chi Yun, Xiong Qingfang, Tan Chee Wah, Yi Yongxiang, Wang Lin-Fa. An unusual COVID-19 case with over four months of viral shedding in the presence of low neutralizing antibodies: a case report[J]. The Journal of Biomedical Research, 2020, 34(6): 470-474. DOI: 10.7555/JBR.34.20200099
    [6]Yun Yangfang, Song Hengyi, Ji Yin, Huo Da, Han Feng, Li Fei, Jiang Nan. Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification[J]. The Journal of Biomedical Research, 2020, 34(6): 458-469. DOI: 10.7555/JBR.34.20200044
    [7]Gorzalski Andrew J., Hartley Paul, Laverdure Chris, Kerwin Heather, Tillett Richard, Verma Subhash, Rossetto Cyprian, Morzunov Sergey, Van Hooser Stephanie, Pandori Mark W.. Characteristics of viral specimens collected from asymptomatic and fatal cases of COVID-19[J]. The Journal of Biomedical Research, 2020, 34(6): 431-436. DOI: 10.7555/JBR.34.20200110
    [8]Mehta Neha, Qiao Renli. Medical management of COVID-19 clinic[J]. The Journal of Biomedical Research, 2020, 34(6): 416-421. DOI: 10.7555/JBR.34.20200118
    [9]Slonim Anthony D., See Helen, Slonim Sheila. Challenges confronting rural hospitals accentuated during COVID-19[J]. The Journal of Biomedical Research, 2020, 34(6): 397-409. DOI: 10.7555/JBR.34.20200112
    [10]Yang Wei. Editorial commentary on special issue of COVID-19 pandemic[J]. The Journal of Biomedical Research, 2020, 34(6): 395-396. DOI: 10.7555/JBR.34.20200701
  • Cited by

    Periodical cited type(3)

    1. Ranjbar M, Asadi M, Nourigorji M, et al. Development of a recombinant nucleocapsid protein-based ELISA for the detection of IgM and IgG antibodies to SARS-CoV-2. Biotechnol Appl Biochem, 2021. DOI:10.1002/bab.2308. Online ahead of print
    2. Castillo-Olivares J, Wells DA, Ferrari M, et al. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases. Front Immunol, 2021, 12: 748291. DOI:10.3389/fimmu.2021.748291
    3. Qasem A, Shaw AM, Elkamel E, et al. Coronavirus Disease 2019 (COVID-19) Diagnostic Tools: A Focus on Detection Technologies and Limitations. Curr Issues Mol Biol, 2021, 43(2): 728-748. DOI:10.3390/cimb43020053

    Other cited types(0)

Catalog

    Article Metrics

    Article views (5700) PDF downloads (309) Cited by(3)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return